The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands

AIM: When glycaemic control for people with type 2 diabetes is not achieved with metformin and sulfonylurea alone, adding another oral anti‐diabetes drug, such as a sodium–glucose co‐transporter 2 (SGLT2) or dipeptidyl peptidase‐4 (DPP‐4) inhibitor, is an alternative to starting insulin. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Van der Linden, N., Van Olst, S., Nekeman, S., Uyl‐de Groot, C.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research: Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048925/
https://www.ncbi.nlm.nih.gov/pubmed/32745279
http://dx.doi.org/10.1111/dme.14371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048925/
https://www.ncbi.nlm.nih.gov/pubmed/32745279
http://dx.doi.org/10.1111/dme.14371

Ejemplares similares